Treatment in persistent genital arousal disorder: a scoping review
- 19 September 2024
- journal article
- review article
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 37 (6) , 970-975
Abstract
Persistent genital arousal disorder (PGAD) is a rare condition characterized by unwanted and distressing symptoms of arousal and dysesthesia. The aim of this scoping review was to map the current state of PGAD management, identify gaps in the literature, and understand patient perspectives. We completed a scoping review following guidelines from the Joanna Briggs Institute and the Preferred Reporting Items for Systematic Reviews and Meta Analyses Scoping Reviews extension. A systematic literature search for articles pertaining to PGAD/genito-pelvic dysesthesia (GPD) was conducted in August 2023 via Medline, Embase, Scopus, and Web of Science. The search returns were deduplicated and the remaining titles and abstracts were screened for inclusion. General publication characteristics and treatment data were extracted from the included publications via a pilot-tested Google form. All screening and extraction were completed in a masked, duplicate fashion. Findings from our scoping review revealed a scarcity of systematic research, limited evidence-based data, and the importance of addressing both physical and psychiatric concerns. Our sample included 46 publications from an initial pool of 636 returns. Case studies were the most common study design. Thirty-three studies examined medication, either alone or as part of a treatment regimen. Selective serotonin reuptake inhibitors were the most used medication, followed by pramipexole and carbamazepine. Seven studies used a surgical or procedural intervention. Treatment with pelvic floor Botox was the most common procedure. Patient perspectives in the included case studies highlighted themes of shame, suicidal ideation, social isolation, decreased sleep, and overall decline in quality of life. The findings from our study emphasize patients’ distressing and psychiatric symptoms, indicating a need to improve treatment regimens, using both evidence-based research outcomes and patient-reported outcomes. Management for PGAD/GPD lacks a standardized framework, indicating a need for further research and the development of clinical practice guidelines to improve patient care.Keywords
This publication has 21 references indexed in Scilit:
- Selective serotonin reuptake inhibitors, post‐treatment sexual dysfunction and persistent genital arousal disorder: A systematic reviewPharmacoepidemiology and Drug Safety, 2023
- Psychological Treatment of Persistent Genital Arousal Disorder/Genitopelvic Dysesthesia Using an Integrative ApproachArchives of Sexual Behavior, 2023
- Persistent Genital Arousal Disorder: Two Case Studies and Exploration of a Novel Treatment ModalityWomen's Health Reports, 2023
- Lamotrigine-Induced Persistent Genital Arousal Disorder and a Potential TreatmentJournal of Sex & Marital Therapy, 2022
- International Society for the Study of Women’s Sexual Health (ISSWSH) Review of Epidemiology and Pathophysiology, and a Consensus Nomenclature and Process of Care for the Management of Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia (PGAD/GPD)The Journal of Sexual Medicine, 2021
- Persistent Genital Arousal Disorder After Motor Vehicle Accident: A Case ReportWomen's Health Reports, 2020
- A Comparison of Medical Comorbidities, Psychosocial, and Sexual Well-being in an Online Cross-Sectional Sample of Women Experiencing Persistent Genital Arousal Symptoms and a Control GroupThe Journal of Sexual Medicine, 2019
- Case Report: Persistent Genital Arousal Disorder in an Adolescent WomanJournal of Pediatric and Adolescent Gynecology, 2019
- Case Reports of a Mother and Daughter Diagnosed With Persistent Genital Arousal DisorderJournal of Sex & Marital Therapy, 2016
- Hypnotherapy for Persistent Genital Arousal Disorder:A Case StudyInternational Journal of Clinical and Experimental Hypnosis, 2014